

SYNTHESIS, CHARACTERIZATION AND ANTIBACTERIAL ACTIVITY OF 2-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES

BNB. Vaidehi*, K. Gnana Deepika¹, RV. Satya, RR. Bangaramma, R. Harish Kumar, Y. Ratna Sudha and T. Ravi Kumar

Sri Sai Aditya Institute of pharmaceutical sciences and Research, Adb road, Surampalem, East Godavari District, Andhra Pradesh, India.

ABSTRACT

Some 2- substituted benzimidazole derivatives were synthesized by condensation of o-phenylenediamine with carboxylic acid in presence of ring closing agents (polyphosphoric acid/HCl). The Chemical structures of synthesized compounds were identified by spectral analysis. The synthesized compounds were screened for their in-vitro antibacterial activity against Standard strains by cup plate method.


Keywords: Benzimidazole, Antibacterial activity, Polyphosphoric acid.

INTRODUCTION

Benzimidazole is a heterocyclic compound consists of benzene ring fused with imidazole ring. The chemistry and pharmacology of benzimidazoles have been of great interest to medicinal chemistry^{1,2}, because its derivatives possessed various biological activities such as anticancer³, antihypertensive⁴, anthelmintic⁵⁻⁷, anti-protozoal^{8,9}, antimicrobial⁽¹⁰⁻¹⁵⁾, antioxidant^{16,17}, anti-inflammatory^{18,19}, analgesic²⁰ and anti-hepatitis-B-virus²¹. Moreover benzimidazoles are important intermediates in organic reaction.^{22,23} A number of methods have been reported for the synthesis of benzimidazoles and its derivatives. These methods include the coupling of o-phenylenediamine with carbonyl compounds in presence of various catalysts like $ZrCl_4$, $SnCl_4 \cdot 5H_2O$, BF_3Et_2O , polyethylene glycol, ceric ammonium nitrate²⁴. In present study we reported the synthesis of 2-alkyl & aryl substituted benzimidazole derivatives in presence of ring closing agents and screened for anti bacterial activity.

MATERIAL AND METHODS

All the chemicals solvents used for this work were obtained from s d fine-chem limited (SDFCL), MUMBAI. Melting point of synthesized compounds were determined in open capillary tube using kshitij melting point apparatus, expressed in °C and were uncorrected silica gel chromatographic plates were used for TLC and solvent systems were ethylacetate : n-hexane (7:3) for all compounds. The purity of the compounds was checked by TLC and spots were visualised by iodine vapours²⁵. IR spectra were recorded in KBr on bruker FT-IR spectrometer. The synthesis of compounds were carried according to scheme-1



Scheme-1

General Procedure for the Synthesis of 2-Substituted Benzimidazoles

Ortho Phenylenediamine (1mole) was made to condense with carboxylic acid derivatives (1mole) in presence of ring closing agents like hydrochloric acid or polyphosphoric acid. The mixture was kept for reflux and progress of the reaction was monitored by TLC. On completion of reaction, the reaction mixture was cooled and poured on to crushed ice. The cooled mixture was made basic by the gradual addition of concentrated ammonia solution. The precipitated product was then filtered and recrystallized from hot water. Decolourise with charcoal if necessary.

IR spectral data of synthesized compounds

- 1H-benzo[d]imidazole(BZ): IR (KBr) cm^{-1} : 3413.67 (aromatic-NH stretching), 1477.77 (-C=C stretching), 1620 (-C=N stretching), 3113.81 (=C-H stretching), 1272.85 (-C-N stretching), 1409.16 (aromatic -NH bending).
- 2-Methyl-1H-benzo[d]imidazole(MBZ): IR (KBr) cm^{-1} : 3445.38 (aromatic-NH stretching), 1462.98 (-C=C stretching), 1556.17 (-C=N stretching), 3176.26 (=C-H stretching), 1270.86 (-C-N stretching), 1477.09 (aromatic -NH bending), 2994.57 and 2874.95 (aliphatic- CH_3 Stretching), 1386.23 (aliphatic - CH_3 bending).
- 2-(Chloromethyl)-1H-benzo[d]imidazole(CIBZ): IR (KBr) cm^{-1} : 3390.67 (aromatic-NH stretching), 1511.60 (-C=C stretching), 1676.80(-C=N stretching), 3055.76 (=C-H stretching), 1271.04 (-C-N stretching), 1430.42(aromatic -NH bending), 742.55 (-C-Cl).
- 4-(1H-benzo[d]imidazol-2-yl)aniline(PABZ): IR (KBr) cm^{-1} : 3385.05 (aromatic-NH stretching), 3470.12 (aromatic - NH_2 stretching), 1500.59 (-C=C stretching), 1605.21 (-C=N stretching), 3143.35 (=C-H stretching), 1274.01 (-C-N stretching), 1444.98 (aromatic -NH bending).

Antibacterial Activity

The compounds were tested for their *in vitro* growth inhibitory activity against different bacteria.


The various organisms like *Staphylococcus aureus* ATCCBAA 1026, *Bacillus subtilis* ATCC 11774, *Staphylococcus wernerii* ATCC 27836 (all Gram positive) and *Pseudomonas aeruginosa* ATCC 10662, *Proteus mirabilis* ATCC 14153 (all Gram negative) were procured from Microbes Speciality Lab, Danavaipeta, Rajahmundry, East Godavari District 533103, Andhra Pradesh, India. The inhibition zones of synthesized compounds were determined using cup plate method²⁶. The sterilized medium (autoclaved at 121°C for 20min) was inoculated using 18hr slant cultures of the test organisms and transferred into sterile petri dishes and allowed to solidify the media. Cups of 8mm diameters were made on solidified media. Solutions of the synthesized compounds at a concentration of 50 $\mu\text{g/ml}$ and 100 $\mu\text{g/ml}$ were prepared in DMSO. 50 μl of each solution was placed in cups by means of sterile pipette. In each plate one cup was used for standard and other two for test solutions. The plates thus prepared were left for 90min in a refrigerator for diffusion. The plates were incubated at 37°C for 24hrs and examined for inhibition zones. The experiment was performed in duplicate and the average diameter of the zones of inhibition was recorded. Gentamycin (50 $\mu\text{g/ml}$) was used as standard.

RESULTS AND DISCUSSION

Chemistry

Different types of organic acids (aliphatic and aromatic) were used to condense with o-phenylenediamine to synthesise 2-substituted benzimidazoles^{27, 28}. The purity of synthesized compounds was checked by TLC and melting point. The physicochemical data of all synthesized compounds was represented in **table 1**. The synthesized compounds were analyzed by Infrared Spectroscopy.

Table 1

ENTRY	ACID	SUBSTITUTION	MOLECULAR FORMULA	MOLECULAR WEIGHT	MELTING POINT	TIME [MIN]	PERCENTAGE YIELD	RF VALUE
1.	HCOOH [FORMICACID]	-H	$\text{C}_7\text{H}_6\text{N}_2$	118gms	170°C	30	73.5	0.575
2.	CH_3COOH [ACETIC ACID]	- CH_3	$\text{C}_8\text{H}_8\text{N}_2$	132.16gms	180°C	45	50	0.68
3.	$\text{NH}_2\text{C}_6\text{H}_4\text{COOH}$ H [PABA]		$\text{C}_{12}\text{H}_{22}\text{N}_3$	209.25gms	310°C	120	31.1	0.88
4.	ClCH_2COOH [CHLOROACETIC ACID]	- CH_2Cl	$\text{C}_8\text{H}_7\text{N}_2\text{Cl}$	166.61gms	210°C	45	54.6	0.565

The *in vitro* antibacterial activity was performed using cup plate method with different strains of gram positive and gram negative bacteria. Gentamycin was used as standard. The results of final compounds for antibacterial activity were recorded in **table2** & **figure1,2**. The results revealed that synthesized compounds showed varying degree of inhibition against the tested


microorganisms. In general, the inhibitory activity against gram positive bacteria was higher than that of gram negative bacteria. Among the synthesized compounds, CIBZ showed potential antibacterial activity. The activity was due to the presence of halogen on substituent at C-2 of benzimidazole ring.

Table 2: Antibacterial Activity of Synthesized Compounds


Entry	Compound	ZONE OF INHIBITION (mm)									
		Gram positive bacteria						Gram negative bacteria			
		S. aureus		B. subtilis		S. weneri		P. mirabilis		P. aeruginosa	
		50 µg/ml	100 µg/ml	50 µg/ml	100 µg/ml	50 µg/ml	100 µg/ml	50 µg/ml	100 µg/ml	50 µg/ml	100 µg/ml
1	BZ	8	12	11	14	17	18	10	12	10	13
2	MBZ	10	14	13	19	16	19	11	15	16	19
3	CIBZ	12	17	18	22	24	27	14	19	17	22
4	PABZ	14	19	16	20	22	25	13	17	18	21
5	Control	-	-	-	-	-	-	-	-	-	-
6	STANDARD (Gentamycin 50 µg/ml)	15		20		24		18		20	

Control – DMSO, -- No activity

Staphylococcus aureus



Bacillus subtilis








Fig. 1: Zone of Inhibition of Synthesized compounds against Gram Positive organisms



Note: Standard (STD) = GENTAMYCIN

Fig. 2: Zone of Inhibition of Synthesized compounds against Gram Negative organisms

CONCLUSION

A simple, convenient, synthetic method was developed for synthesis of 2-substituted benzimidazoles. Among the synthesized compounds, CIBZ exhibited prominent antibacterial activity. Further analysis of structure by NMR, Mass Spectroscopy is required to interpret the synthesized compounds. More extensive study is needed to confirm the mode of action studies to optimize the effectiveness of these compounds.

REFERENCES

1. (a)Wright JB. Chem Rev. 1951;48: 397. (b)Preston PN. Chem Rev.1974; 74:297.
2. (a) Preston PN. In Benzimidazole and congeneric tricyclic compounds (eds) A. Weissberger and E. C. Taylor (New York: John Wiley and Sons), 1980; 2, 63-147; (b) Grimmett MR. In comprehensive heterocyclic chemistry (ed.) K T Pots (oxford:pergimon), 1984;345-498. (c) Hoffman K. In Imidazole and its derivatives (ed.) A Weissberger; The chemistry of heterocyclic compounds (New York: Interscience Publishers, Inc), 1953; 247-317
3. Starcevic K, Kraji M, Ester K, Sabol I, grce M, pavelic K and Karminski-zamola G. Bioorg Med Chem. 2007; 15:4419.
4. Kubo K, Inada Y, Kohara Y, Sugiura Y, Ojima M, Itoh K, Furukawa Y, Nishikawa YK and Naka T. J Med. Chem. 1993; 36: 1772.
5. Dubay R, Abuzar S, Sharma S, Chatterjee RK and Katiyar JC. J Med Chem. 1985;28:1748.
6. Mavrova AT, Denkova PS, Tsenov Y A, Anichina KK and Vutchev DL. Bioorg Med Chem. 2007;15:6291.
7. Ravina E , Sanchez-Alonso R, Fueyo J, Baltar MP ,Bos J, Iglesias R and Sanmartin ML. Arzneim Forsch. 1993; 43:684.
8. Navarette-Vazquez G, Cedilla R, Hernandez-Campos A, Yopez A, Hernandez-luis F, Valdez J, Morels R and Cortes R , Hernandez M and Castillo R. Bioorg Med Chem. 2001; 11:187.
9. Katiyar SK, Gordon VR, Mc Laughlin GL and Edlind TD. Antimicrob Agents Chemother. 1994;38:2986.
10. Goker H, kus C, Boykin DW , Yildiz S and Altanlar N. Bioorg Med Chem. 2002;10:2589
11. Goker H, Ozden S, Yildiz S, and Boykin DW. Eur J Med Chem. 2005; 40:1062
12. Desai KG and Desai KR. Bioorg Med Chem. 2006;14:8271
13. Kazimierczuk Z, Upcroft JA, Upcroft P, Gorska A, Starosciak B and Laudy A. Acta Biochim Polon. 2002;49:185
14. Mohammad BG, Hussien MA, Abdel-Alim AA and Hashem M. Arch Pharm. Res. 2006; 29:26.
15. Pawar NS, Dalal DS, Shimpi SR and Mahulikar PP. Eur J Pharm Sci. 2004; 21:115.
16. Kus C, Ayhan-Kilcigil G, Can Eke B and Iscan N. Arch Pharma Res. 2004; 27:156.
17. Ates-Alagoz A, Kus C and Coban T. J Enzyme Inhib Med Chem. 2005;20: 325.
18. Lazer ES, Matteo MR and Possanza GJ. J Med Chem. 1987;30:726.
19. Lackner TE and Clissold SP. Drugs. 1989; 38: 204.
20. Ito K, Kagaya H, Fukuda E, Yoshino K and Nose T. Arznein. Forsch. Drug Res. 1982; 32:49 .
21. Li YF, Wang GF, He PL ,Huang WG, zhu FH, Gao HY, Tang W, Luo Y, Feng CL, Shi LP, Ren YD, Lu W and Zuo JP. J Med Chem. 2006; 49:4790.
22. Grimmet M R in (eds) Katritzky A R C W Rees. Hetero.chem. 1984; 457
23. Czarny A, Wilson WD and Boykin D W. J Heterocyclic chem. 1996;33: 1393.
24. (a) Zhang ZH; Yin L, Li Y, Wang YM, Catal Commun. 2007;8:1126. (b) Zhang ZH, Yin L, Li Y, Wang YM, Tetrahedron Lett. 2005;46:889.
25. Green H and Day AR. The Tautomeric Character of the Imidazole ring, J.Am.Chem.Soc, 1942;64:1167-1173.
26. Hawkey PM, Lewis DA. *Medical bacteriology-a practical approach*, Oxford University press, United Kingdom, 1994;181.
27. Furniss BS, Hannaford AJ, Peter WG, Smith and Tetchell AR, *Vogel's Text book of Practical Organic Chemistry*, 1989; 5th ed., 1162-63.
28. Ansari KF. Lal C *J Chem Sci*. 2009; 121(6):1017-1025.